Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I previously outlined how I thought leronlimab's disruption of the mTOR pathway could act as an antiviral by stopping virus splitting. Disruption of mTOR also downregulates neuropilin-1. So now we know of 2 and possibly 3 ways leronlimab acts against the virus.
It is very easy to "prove" anything when it's taken completely out of context. Have you even bothered to read the paper that the false "masks don't work" claims are based on? Of course not, that would go against your preconceived notions. There is no need to go to any fact checking site. All that you need to do is to read the original study and apply a little common sense and logic.
In no way shape or form does the study prove the futility in wearing masks. The study was looking at COVID-19 incident rate for those in close contacts with others including community contact and those with COVID-19.
Most in the group said they always or almost always wore a mask. But where the close contacts were statistically significant were in settings where masks would not be worn. Exposure to family members, bars and restaurants. So the link you posted is complete nonsense. Unless of course you think people wear their masks at home all the time, drink through their masks and masticate their food so thoroughly they can get it past the filtration of the mask.
https://www.cdc.gov/mmwr/volumes/69/wr/pdfs/mm6936a5-H.pdf
The heady old days of a high flying stock.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153441971
That means you're screwed. But of course any statement from the company means you're screwed.
Nice bit of sarcasm.
Actually much better than HGEN. They had one guy go from high flow cannula oxygen to low flow cannula oxygen in 7 days. Compared to taking people off of ECMO and intubation that's just pathetic.
The FDA wanted the data from the monotherapy trial that was collected between January 2020 and June 2020 (end of trial). We do have someone highly experienced at BLA submission and I think it was said, well known by the FDA, who has been hired to handle the BLA submission for HIV combo therapy. Which will allow Amarex to concentrate on COVID-19 and yes Amarex has quite a few BLA submissions that led to approval.
EIND is the application that is used for single patient expanded access. Leronlimab had it's EINDs shut down to facilitate the trial. They're not about to open usage to broader groups.
Just more FUD.
I've previously shown how CCR5 increases bradykinin. CCR5 also upregulates IFNy and is necessary for IFNb to activate macrophages. CCR5 blockade is the regulator. A "doctor" should realize all roads lead to CCR5.
For the Berend's karma will be soaking up the sunshine in Brazil on stockholders money once the coronavirus dies down.
I said that back in January when DrugDoctor was pumping the hell out of this stock.
Was that $1.50 worth?
Karen come and save us!!!!!
I step away from this board for 5 months and I find that a half dozen people aren't in jail yet. I'm very disappointed in the SEC. But even more disappointed there aren't new videos of L4L shoes in stores.
One of the studies they cite is from Spain. Which supposedly shows improved mortality rate for Hydroxy with p <.001. A quite flawed study. Do you want to know why? Tocilizumab also showed reduced mortality rate 0f p <.001. We know from an actual double-blinded placebo controlled study that Tocilizumab is a complete fail.
Another study is the Henry Ford study. Quite a few of the patients were also treated concomitantly with corticosteroids and being a retroactive look there's no way to differentiate which of the drugs had effect. However we do know from a controlled study that corticosteroids do have effect.
The last study cited was out of Belgium, yet another retroactive look. The treatment arm was Hydroxy with other forms of treatment, with no specificity of what that treatment was.
All of this time and not a single double-blinded placebo controlled study of Hydroxy. You would think one of the quack doctors that support it would have done one by now.
We know who hasn't bought back in yet.
Which myth? The one that you're an early shareholder and didn't just hunt through SEC documents. Of course the CEO would sign a contract. It says nothing about who brought the molecule to the company. That Van Ness was exited and Nader took his place is meaningful.
But bradykinin does nothing unless it binds to one of its receptors. Far less BR1 with CCR5 blockade and when it binds to BR2 it's acts as an anti-inflammatory.
As if popularity dictates how science works.
TNF-alpha and IFN-gamma (both downregulated by CCR5 blockade) are responsible for upregulating the kinin B1 receptor which is where bradykinin binds. So bradykinin is CCR5 dependent.
Which stock? We know it's not CYDY.
If Cytodyn continues to outsource it will remain a small shop. Does a company with possibly 40 employees need 25 million shares as incentive over the next year. I really don't think so. Then we come to the evergreen provision that will give stockholders no further say in amending the 2012 compensation plan. Nader himself says he wants to minimize dilution so a no vote would be complying with his wishes.
If Nader wants more yes votes he needs to explain why he needs such an extravagant amount of shares. The recent bonuses and attempted bonuses tell me he won't provide any answers.
Charts don't lie, some who interpret them that's another story.
If TA fails then try and discredit the science. Except the science is valid and has proven to be more effective then the approved treatments. Which makes the intent that has existed all along quite obvious.
What defense is needed? Inflammation is what upregulates bradykinin production. Shut down the inflammation with leronlimab and you don't see increased bradykinin. The scientists saying the cause of complications is a bradykinin storm rather than cytokine storm have it ass backwards.
26 indications? There will be more added as I do additional research.
Leronlimab - Disease List (currently 65)
(updated 7-17-2020)
An incomplete list of potential treatment targets for leronlimab.
Acute Respiratory Distress Syndrome
Allergies (anaphylactic shock)
Alopecia Areata
Alzheimer's
Amyotrophic Lateral Sclerosis
Anthrax
Asthma
Atherosclerosis
Atopic Dermatitis
Cancer
Castleman Disease
Coeliac Disease
Chronic Fatigue Syndrome
Chronic Kidney Disease (underlying pathologies)
COPD
COVID-19 (and other coronaviruses)
Crohn's Disease
Colitis
Dermatomyositis
Diabetes (type 1 and 2)
Duchenne Muscular Dystrophy (possibly other muscular dystrophies also)
Emphysema
Endometriosis
Fibromyalgia
Gout
Grave’s Disease
Guillain-Barre Syndrome
GVHD
Hashimoto’s Thyroiditis
Hepatitis (autoimmune)
HIV
Idiopathic Pulmonary Fibrosis
Inflammatory Bowel Disease
Influenza (severe)
Kawasaki Syndrome
Lambert-Eaton Syndrome
Lewy Body Dementia
Lupus
Lyme Disease
Marshall’s syndrome (PFAPA)
Miller Fisher Syndrome
Multiple Sclerosis
Myasthenia Gravis
Myocarditis
NASH
Neurofibromatosis
Osteomyelitis
Parkinson's Disease
Pemphigus
Pneumonia
Polymyositis
Post-Myocardial Infarction Syndrome
Psoriasis
Pulmonary Arterial Hypertension
Pulmonary Fibrosis
Rheumatic Fever
Rheumatoid Arthritis
Sarcoidosis
Scleroderma
Sepsis
Sickle Cell Disease (anti-inflammatory and anti-hypercoagulability effect)
Sjogren’s Syndrome
Stroke
Tuberculosis
Vasculitis
That's standard for at least 95% of the TA traders out there.
From a post I made a long time ago.
Unless you have NP's office and phones bugged that's nothing but pure speculation. Which you've been doing for years when you want to buy back in.
Thank the corrupt FDA for that.
What was the name of the company?
Almost two shares now only one when it goes to $5.95.